Rottinghaus Scott T. 4
4 · ENANTA PHARMACEUTICALS INC · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Enanta (ENTA) CMO Scott Rottinghaus Receives Stock Awards
What Happened
- Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals (ENTA), was issued a total of 6,875 shares on Feb 12, 2026 from performance-based awards (1,650 + 5,225 shares; award price $0). As part of the settlement, 3,413 shares were automatically withheld/disposed to cover withholding taxes, reported at $14.25 per share for a value of $48,635.
Key Details
- Transaction date: February 12, 2026; Form 4 filed February 13, 2026 (timely).
- Awards issued: 1,650 shares (PSUs) and 5,225 shares (rTSRU), both settled in stock at $0 acquisition price.
- Withholding/tax disposition: 3,413 shares withheld at $14.25/share (total $48,635) to satisfy tax obligations.
- Shares owned after transaction: Not disclosed in the filing.
- Transaction codes: A = Award/Grant; F = tax withholding/payment of exercise price.
- Footnotes: PSUs vested based on two-year R&D milestones (2024–2025); rTSRUs vested based on relative total shareholder return vs. Nasdaq Biotech Index over two-year periods; withheld shares represent automatic forfeiture to cover taxes.
Context
- These were performance-vesting awards settled in stock, not open-market purchases or sales. The automatic forfeiture of shares to cover taxes is a common settlement practice and does not necessarily indicate a buy/sell market signal.
Insider Transaction Report
Form 4
Rottinghaus Scott T.
Chief Medical Officer
Transactions
- Award
Common Stock
[F1]2026-02-12+1,650→ 23,442 total - Award
Common Stock
[F2]2026-02-12+5,225→ 28,667 total - Tax Payment
Common Stock
[F3]2026-02-12$14.25/sh−3,413$48,635→ 25,254 total
Footnotes (3)
- [F1]Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026.
- [F2]Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026.
- [F3]Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Signature
/s/ Matthew Kowalsky as attorney-in-fact|2026-02-13